Mitochondria, Cybrids, Aging, and Alzheimer's Disease

Progress in Molecular Biology and Translational Science

Volumn 146, Issue , 2017, Pages 259-302

  Swerdlow, R H ^a   Koppel, S ^a   Weidling, I ^a   Hayley, C ^a   Ji, Y ^a   Wilkins, H M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Alzheimer's disease; Bioenergetics cybrids; Mitochondria

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FREE RADICAL; MITOCHONDRIAL DNA;

AGING; ALZHEIMER DISEASE; CYBRID; GENE MUTATION; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; LONGEVITY; MATERNAL INHERITANCE; MITOCHONDRION; NONHUMAN; SOMATIC MUTATION; ANIMAL; CYTOPLASM; GENETICS; INHERITANCE; METABOLISM; PATHOLOGY;

AGING; ALZHEIMER DISEASE; ANIMALS; CYTOPLASM; DNA, MITOCHONDRIAL; HUMANS; INHERITANCE PATTERNS; MITOCHONDRIA;

EID: 85011074176     PISSN: 18771173     EISSN: 18780814     Source Type: Book Series    
DOI: 10.1016/bs.pmbts.2016.12.017     Document Type: Chapter

References (280)

1. Lewis, M.R., Lewis, W.H., Mitochondria in tissue culture. Science 39 (1914), 330–333.
2. Nass, M.M., Nass, S., Intramitochondrial fibers with DNA characteristics. I. Fixation and electron staining reactions. J Cell Biol 19 (1963), 593–611.
3. Nass, S., Nass, M.M., Intramitochondrial fibers with DNA characteristics. II. Enzymatic and other hydrolytic treatments. J Cell Biol 19 (1963), 613–629.
4. Mitchell, P., Moyle, J., Chemiosmotic hypothesis of oxidative phosphorylation. Nature 213 (1967), 137–139.
5. Harman, D., The biologic clock: the mitochondria?. J Am Geriatr Soc 20 (1972), 145–147.
6. Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., The hallmarks of aging. Cell 153 (2013), 1194–1217.
7. Muller, F.L., Lustgarten, M.S., Jang, Y., Richardson, A., Van Remmen, H., Trends in oxidative aging theories. Free Radic Biol Med 43 (2007), 477–503.
8. Swerdlow, R.H., Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?. Neurobiol Aging 28 (2007), 1465–1480.
9. Swerdlow, R.H., Kish, S.J., Mitochondria in Alzheimer's disease. Int Rev Neurobiol 53 (2002), 341–385.
10. Swerdlow, R.H., The neurodegenerative mitochondriopathies. J Alzheimers Dis 17 (2009), 737–751.
11. Osborne, T.B., Mendel, L.B., Ferry, E.L., The effect of retardation of growth upon the breeding period and duration of life of rats. Science 45 (1917), 294–295.
12. McCay, C.M., Crowell, M.F., Maynard, L.A., The effect of retarded growth upon the length of life and upon the ultimate body size. J Nutr 10 (1935), 63–79.
13. McCay, C.M., Maynard, L.A., Sperling, G., Barnes, L.L., Retarded growth, lifespan, ultimate body size, and age changes in the albino rat after feeding diets restricted in calories. J Nutr 18 (1937), 1–13.
14. Carlson, A.J., Hoelzel, F., Apparent prolongation of the life span of rats by intermittent fasting. J Nutr 31 (1946), 363–375.
15. Masoro, E.J., Subfield history: caloric restriction, slowing aging, and extending life. Sci Aging Knowl Environ, 2003, 2003, Re2.
16. Rubner, M., Das Problem der Lebensdauer und seine Bezieung zu Wachstum und Ernehrung [The problem of longevity and its relation to growth and nutrition]. 1908 Oldenburg, Munich.
17. Pearl, R., The Rate of Living, Being an Account of Some Experimental Studies on the Biology of Life Duration. 1928, Alfred A. Knopf, New York.
18. Harman, D., Aging: a theory based on free radical and radiation chemistry. J Gerontol 11 (1956), 298–300.
19. Miquel, J., Economos, A.C., Fleming, J., Johnson, J.E. Jr., Mitochondrial role in cell aging. Exp Gerontol 15 (1980), 575–591.
20. Linnane, A.W., Marzuki, S., Ozawa, T., Tanaka, M., Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1 (1989), 642–645.
21. Wallace, D.C., Mitochondrial genetics: a paradigm for aging and degenerative diseases?. Science 256 (1992), 628–632.
22. Trifunovic, A., Wredenberg, A., Falkenberg, M., et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429 (2004), 417–423.
23. Kujoth, G.C., Hiona, A., Pugh, T.D., et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309 (2005), 481–484.
24. Navarro, A., Boveris, A., The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol 292 (2007), C670–C686.
25. Boveris, A., Navarro, A., Brain mitochondrial dysfunction in aging. IUBMB Life 60 (2008), 308–314.
26. Barrientos, A., Casademont, J., Cardellach, F., Estivill, X., Urbano-Marquez, A., Nunes, V., Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res Mol Brain Res 52 (1997), 284–289.
27. Hirai, K., Aliev, G., Nunomura, A., et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21 (2001), 3017–3023.
28. Stauch, K.L., Purnell, P.R., Fox, H.S., Aging synaptic mitochondria exhibit dynamic proteomic changes while maintaining bioenergetic function. Aging 6 (2014), 320–334.
29. Green, D.R., Galluzzi, L., Kroemer, G., Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 333 (2011), 1109–1112.
30. Stauch, K.L., Purnell, P.R., Villeneuve, L.M., Fox, H.S., Proteomic analysis and functional characterization of mouse brain mitochondria during aging reveal alterations in energy metabolism. Proteomics 15 (2015), 1574–1586.
31. Poon, H.F., Vaishnav, R.A., Getchell, T.V., Getchell, M.L., Butterfield, D.A., Quantitative proteomics analysis of differential protein expression and oxidative modification of specific proteins in the brains of old mice. Neurobiol Aging 27 (2006), 1010–1019.
32. Finkel, T., Oxidant signals and oxidative stress. Curr Opin Cell Biol 15 (2003), 247–254.
33. Finkel, T., Reactive oxygen species and signal transduction. IUBMB Life 52 (2001), 3–6.
34. Haynes, C.M., Fiorese, C.J., Lin, Y.F., Evaluating and responding to mitochondrial dysfunction: the mitochondrial unfolded-protein response and beyond. Trends Cell Biol 23 (2013), 311–318.
35. Kotiadis, V.N., Duchen, M.R., Osellame, L.D., Mitochondrial quality control and communications with the nucleus are important in maintaining mitochondrial function and cell health. Biochim Biophys Acta 1840 (2014), 1254–1265.
36. Schulz, T.J., Zarse, K., Voigt, A., Urban, N., Birringer, M., Ristow, M., Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab 6 (2007), 280–293.
37. Gomez-Cabrera, M.C., Domenech, E., Romagnoli, M., et al. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am J Clin Nutr 87 (2008), 142–149.
38. Ristow, M., Zarse, K., Oberbach, A., et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 106 (2009), 8665–8670.
39. Payne, B.A., Wilson, I.J., Yu-Wai-Man, P., et al. Universal heteroplasmy of human mitochondrial DNA. Hum Mol Genet 22 (2013), 384–390.
40. Ye, K., Lu, J., Ma, F., Keinan, A., Gu, Z., Extensive pathogenicity of mitochondrial heteroplasmy in healthy human individuals. Proc Natl Acad Sci USA 111 (2014), 10654–10659.
41. Mecocci, P., MacGarvey, U., Kaufman, A.E., et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 34 (1993), 609–616.
42. Bohr, V.A., Dianov, G.L., Oxidative DNA damage processing in nuclear and mitochondrial DNA. Biochimie 81 (1999), 155–160.
43. Hudson, E.K., Hogue, B.A., Souza-Pinto, N.C., et al. Age-associated change in mitochondrial DNA damage. Free Radic Res 29 (1998), 573–579.
44. Richter, C., Reactive oxygen and DNA damage in mitochondria. Mutat Res 275 (1992), 249–255.
45. Nie, B., Gan, W., Shi, F., et al. Age-dependent accumulation of 8-oxoguanine in the DNA and RNA in various rat tissues. Oxid Med Cell Longev, 2013, 2013, 303181.
46. Corral-Debrinski, M., Horton, T., Lott, M.T., Shoffner, J.M., Beal, M.F., Wallace, D.C., Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet 2 (1992), 324–329.
47. Brand, F.N., Kiely, D.K., Kannel, W.B., Myers, R.H., Family patterns of coronary heart disease mortality: the Framingham Longevity Study. J Clin Epidemiol 45 (1992), 169–174.
48. Tanaka, M., Gong, J.S., Zhang, J., Yoneda, M., Yagi, K., Mitochondrial genotype associated with longevity. Lancet 351 (1998), 185–186.
49. Ross, O.A., McCormack, R., Curran, M.D., et al. Mitochondrial DNA polymorphism: its role in longevity of the Irish population. Exp Gerontol 36 (2001), 1161–1178.
50. Ivanova, R., Lepage, V., Charron, D., Schachter, F., Mitochondrial genotype associated with French Caucasian centenarians. Gerontology, 44, 1998, 349.
51. Torroni, A., Huoponen, K., Francalacci, P., et al. Classification of European mtDNAs from an analysis of three European populations. Genetics 144 (1996), 1835–1850.
52. Ruiz-Pesini, E., Mishmar, D., Brandon, M., Procaccio, V., Wallace, D.C., Effects of purifying and adaptive selection on regional variation in human mtDNA. Science 303 (2004), 223–226.
53. De Benedictis, G., Rose, G., Carrieri, G., et al. Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. FASEB J 13 (1999), 1532–1536.
54. Niemi, A.K., Hervonen, A., Hurme, M., Karhunen, P.J., Jylha, M., Majamaa, K., Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. Hum Genet 112 (2003), 29–33.
55. Khrapko, K., Vijg, J., Mitochondrial DNA mutations and aging: devils in the details?. Trends Genet 25 (2009), 91–98.
56. Vermulst, M., Bielas, J.H., Kujoth, G.C., et al. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 39 (2007), 540–543.
57. Vermulst, M., Wanagat, J., Kujoth, G.C., et al. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 40 (2008), 392–394.
58. Kukat, A., Trifunovic, A., Somatic mtDNA mutations and aging—facts and fancies. Exp Gerontol 44 (2009), 101–105.
59. Hughes, B.G., Hekimi, S., A mild impairment of mitochondrial electron transport has sex-specific effects on lifespan and aging in mice. PLoS One, 6, 2011, e26116.
60. Foster, N.L., Chase, T.N., Fedio, P., Patronas, N.J., Brooks, R.A., Di Chiro, G., Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 33 (1983), 961–965.
61. de Leon, M.J., Ferris, S.H., George, A.E., et al. Positron emission tomographic studies of aging and Alzheimer disease. AJNR Am J Neuroradiol 4 (1983), 568–571.
62. Swerdlow, R., Marcus, D.L., Landman, J., Kooby, D., Frey, W. 2nd, Freedman, M.L., Brain glucose metabolism in Alzheimer's disease. Am J Med Sci 308 (1994), 141–144.
63. Baloyannis, S.J., Mitochondrial alterations in Alzheimer's disease. J Alzheimers Dis 9 (2006), 119–126.
64. Gibson, G.E., Sheu, K.F., Blass, J.P., et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 45 (1988), 836–840.
65. Gibson, G.E., Sheu, K.F., Blass, J.P., Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm 105 (1998), 855–870.
66. Sorbi, S., Bird, E.D., Blass, J.P., Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 13 (1983), 72–78.
67. Gibson, G.E., Starkov, A., Blass, J.P., Ratan, R.R., Beal, M.F., Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim Biophys Acta 1802 (2010), 122–134.
68. Swerdlow, R.H., Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid Redox Signal 16 (2012), 1434–1455.
69. Parker, W.D. Jr., Filley, C.M., Parks, J.K., Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40 (1990), 1302–1303.
70. Bosetti, F., Brizzi, F., Barogi, S., et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging 23 (2002), 371–376.
71. Mancuso, M., Filosto, M., Bosetti, F., et al. Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Exp Neurol 182 (2003), 421–426.
72. Cardoso, S.M., Proenca, M.T., Santos, S., Santana, I., Oliveira, C.R., Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 25 (2004), 105–110.
73. Parker, W.D. Jr., Mahr, N.J., Filley, C.M., et al. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 44 (1994), 1086–1090.
74. Valla, J., Schneider, L., Niedzielko, T., et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 6 (2006), 323–330.
75. Kish, S.J., Bergeron, C., Rajput, A., et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 59 (1992), 776–779.
76. Parker, W.D. Jr., Parks, J., Filley, C.M., Kleinschmidt-DeMasters, B.K., Electron transport chain defects in Alzheimer's disease brain. Neurology 44 (1994), 1090–1096.
77. Mutisya, E.M., Bowling, A.C., Beal, M.F., Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 63 (1994), 2179–2184.
78. Valla, J., Berndt, J.D., Gonzalez-Lima, F., Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. J Neurosci 21 (2001), 4923–4930.
79. Chagnon, P., Betard, C., Robitaille, Y., Cholette, A., Gauvreau, D., Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. Neuroreport 6 (1995), 711–715.
80. Maurer, I., Zierz, S., Moller, H.J., A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 21 (2000), 455–462.
81. Simonian, N.A., Hyman, B.T., Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation. J Neuropathol Exp Neurol 52 (1993), 580–585.
82. Verwer, R.W., Jansen, K.A., Sluiter, A.A., Pool, C.W., Kamphorst, W., Swaab, D.F., Decreased hippocampal metabolic activity in Alzheimer patients is not reflected in the immunoreactivity of cytochrome oxidase subunits. Exp Neurol 163 (2000), 440–451.
83. Wong-Riley, M., Antuono, P., Ho, K.C., et al. Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Res 37 (1997), 3593–3608.
84. Parker, W.D. Jr., Parks, J.K., Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 45 (1995), 482–486.
85. Curti, D., Rognoni, F., Gasparini, L., et al. Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients. Neurosci Lett 236 (1997), 13–16.
86. Wang, X., Su, B., Lee, H.G., et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29 (2009), 9090–9103.
87. Manczak, M., Calkins, M.J., Reddy, P.H., Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet 20 (2011), 2495–2509.
88. Sheng, B., Wang, X., Su, B., et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem 120 (2012), 419–429.
89. Qin, W., Haroutunian, V., Katsel, P., et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 66 (2009), 352–361.
90. Wang, X., Su, B., Fujioka, H., Zhu, X., Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol 173 (2008), 470–482.
91. de la Monte, S.M., Luong, T., Neely, T.R., Robinson, D., Wands, J.R., Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest 80 (2000), 1323–1335.
92. Coskun, P.E., Beal, M.F., Wallace, D.C., Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 101 (2004), 10726–10731.
93. Rodriguez-Santiago, B., Casademont, J., Nunes, V., Is mitochondrial DNA depletion involved in Alzheimer's disease?. Eur J Hum Genet 9 (2001), 279–285.
94. Corral-Debrinski, M., Horton, T., Lott, M.T., et al. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 23 (1994), 471–476.
95. Chang, S.W., Zhang, D., Chung, H.D., Zassenhaus, H.P., The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain. Biochem Biophys Res Commun 273 (2000), 203–208.
96. Hamblet, N.S., Castora, F.J., Elevated levels of the Kearns-Sayre syndrome mitochondrial DNA deletion in temporal cortex of Alzheimer's patients. Mutat Res 379 (1997), 253–262.
97. Casoli, T., Di Stefano, G., Spazzafumo, L., et al. Contribution of non-reference alleles in mtDNA of Alzheimer's disease patients. Ann Clin Transl Neurol 1 (2014), 284–289.
98. Casoli, T., Spazzafumo, L., Di Stefano, G., Conti, F., Role of diffuse low-level heteroplasmy of mitochondrial DNA in Alzheimer's disease neurodegeneration. Front Aging Neurosci, 7, 2015, 142.
99. Mecocci, P., MacGarvey, U., Beal, M.F., Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36 (1994), 747–751.
100. Egensperger, R., Kosel, S., Schnopp, N.M., Mehraein, P., Graeber, M.B., Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases. Neuropathol Appl Neurobiol 23 (1997), 315–321.
101. Fesahat, F., Houshmand, M., Panahi, M.S., Gharagozli, K., Mirzajani, F., Do haplogroups H and U act to increase the penetrance of Alzheimer's disease?. Cell Mol Neurobiol 27 (2007), 329–334.
102. Hutchin, T., Cortopassi, G., A mitochondrial DNA clone is associated with increased risk for Alzheimer disease. Proc Natl Acad Sci USA 92 (1995), 6892–6895.
103. Ienco, E.C., Simoncini, C., Orsucci, D., et al. May “mitochondrial eve” and mitochondrial haplogroups play a role in neurodegeneration and Alzheimer's disease?. Int J Alzheimers Dis, 2011, 2011, 709061.
104. Lakatos, A., Derbeneva, O., Younes, D., et al. Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort. Neurobiol Aging 31 (2010), 1355–1363.
105. Maruszak, A., Canter, J.A., Styczynska, M., Zekanowski, C., Barcikowska, M., Mitochondrial haplogroup H and Alzheimer's disease—is there a connection?. Neurobiol Aging 30 (2009), 1749–1755.
106. Maruszak, A., Safranow, K., Branicki, W., et al. The impact of mitochondrial and nuclear DNA variants on late-onset Alzheimer's disease risk. J Alzheimers Dis 27 (2011), 197–210.
107. Santoro, A., Balbi, V., Balducci, E., et al. Evidence for sub-haplogroup h5 of mitochondrial DNA as a risk factor for late onset Alzheimer's disease. PLoS One, 5, 2010, e12037.
108. Shoffner, J.M., Brown, M.D., Torroni, A., et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 17 (1993), 171–184.
109. Takasaki, S., Mitochondrial haplogroups associated with Japanese Alzheimer's patients. J Bioenerg Biomembr 41 (2009), 407–410.
110. Tanaka, N., Goto, Y., Akanuma, J., et al. Mitochondrial DNA variants in a Japanese population of patients with Alzheimer's disease. Mitochondrion 10 (2010), 32–37.
111. van der Walt, J.M., Dementieva, Y.A., Martin, E.R., et al. Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett 365 (2004), 28–32.
112. Ridge, P.G., Koop, A., Maxwell, T.J., et al. Mitochondrial haplotypes associated with biomarkers for Alzheimer's disease. PLoS One, 8, 2013, e74158.
113. Wang, Y., Brinton, R.D., Triad of risk for late onset Alzheimer's: mitochondrial haplotype, APOE genotype and chromosomal sex. Front Aging Neurosci, 8, 2016, 232.
114. Chinnery, P.F., Taylor, G.A., Howell, N., et al. Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. Neurology 55 (2000), 302–304.
115. Edland, S.D., Tobe, V.O., Rieder, M.J., et al. Mitochondrial genetic variants and Alzheimer disease: a case-control study of the T4336C and G5460A variants. Alzheimer Dis Assoc Disord 16 (2002), 1–7.
116. Rodriguez Santiago, B., Casademont, J., Nunes, V., Is there a relation between Alzheimer s disease and defects of mitochondrial DNA?. Rev Neurol 33 (2001), 301–305.
117. Wragg, M.A., Talbot, C.J., Morris, J.C., Lendon, C.L., Goate, A.M., No association found between Alzheimer's disease and a mitochondrial tRNA glutamine gene variant. Neurosci Lett 201 (1995), 107–110.
118. Zsurka, G., Kalman, J., Csaszar, A., Rasko, I., Janka, Z., Venetianer, P., No mitochondrial haplotype was found to increase risk for Alzheimer's disease. Biol Psychiatry 44 (1998), 371–373.
119. Caspersen, C., Wang, N., Yao, J., et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19 (2005), 2040–2041.
120. Lustbader, J.W., Cirilli, M., Lin, C., et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304 (2004), 448–452.
121. Manczak, M., Anekonda, T.S., Henson, E., Park, B.S., Quinn, J., Reddy, P.H., Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15 (2006), 1437–1449.
122. Crouch, P.J., Blake, R., Duce, J.A., et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 25 (2005), 672–679.
123. Hansson Petersen, C.A., Alikhani, N., Behbahani, H., et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 105 (2008), 13145–13150.
124. Du, H., Guo, L., Fang, F., et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14 (2008), 1097–1105.
125. Dragicevic, N., Mamcarz, M., Zhu, Y., et al. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J Alzheimers Dis 20:suppl 2 (2010), S535–S550.
126. Yamaguchi, H., Yamazaki, T., Ishiguro, K., Shoji, M., Nakazato, Y., Hirai, S., Ultrastructural localization of Alzheimer amyloid beta/A4 protein precursor in the cytoplasm of neurons and senile plaque-associated astrocytes. Acta Neuropathol 85 (1992), 15–22.
127. Yao, J., Du, H., Yan, S., et al. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J Neurosci 31 (2011), 2313–2320.
128. Canevari, L., Clark, J.B., Bates, T.E., Beta-amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett 457 (1999), 131–134.
129. Casley, C.S., Canevari, L., Land, J.M., Clark, J.B., Sharpe, M.A., Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80 (2002), 91–100.
130. Parks, J.K., Smith, T.S., Trimmer, P.A., Bennett, J.P. Jr., Parker, W.D. Jr., Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 76 (2001), 1050–1056.
131. Pereira, C., Santos, M.S., Oliveira, C., Mitochondrial function impairment induced by amyloid beta-peptide on PC12 cells. Neuroreport 9 (1998), 1749–1755.
132. Cardoso, S.M., Santos, S., Swerdlow, R.H., Oliveira, C.R., Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J 15 (2001), 1439–1441.
133. Wang, X., Su, B., Siedlak, S.L., et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 105 (2008), 19318–19323.
134. Anandatheerthavarada, H.K., Biswas, G., Robin, M.A., Avadhani, N.G., Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161 (2003), 41–54.
135. Anandatheerthavarada, H.K., Devi, L., Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease. Neuroscientist 13 (2007), 626–638.
136. Devi, L., Prabhu, B.M., Galati, D.F., Avadhani, N.G., Anandatheerthavarada, H.K., Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 26 (2006), 9057–9068.
137. Lin, M.T., Beal, M.F., Alzheimer's APP mangles mitochondria. Nat Med 12 (2006), 1241–1243.
138. Bassett, S.S., Avramopoulos, D., Fallin, D., Evidence for parent of origin effect in late-onset Alzheimer disease. Am J Med Genet 114 (2002), 679–686.
139. Duara, R., Lopez-Alberola, R.F., Barker, W.W., et al. A comparison of familial and sporadic Alzheimer's disease. Neurology 43 (1993), 1377–1384.
140. Edland, S.D., Silverman, J.M., Peskind, E.R., Tsuang, D., Wijsman, E., Morris, J.C., Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology 47 (1996), 254–256.
141. Mosconi, L., Berti, V., Swerdlow, R.H., Pupi, A., Duara, R., de Leon, M., Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics 4 (2010), 170–193.
142. Mosconi, L., Brys, M., Switalski, R., et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 104 (2007), 19067–19072.
143. Okonkwo, O.C., Xu, G., Oh, J.M., et al. Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer's disease. Cereb Cortex 24 (2014), 978–988.
144. Mosconi, L., Glodzik, L., Mistur, R., et al. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry 68 (2010), 913–921.
145. Mosconi, L., Rinne, J.O., Tsui, W.H., et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci USA 107 (2010), 5949–5954.
146. Honea, R.A., Vidoni, E.D., Swerdlow, R.H., Burns, J.M., Maternal family history is associated with Alzheimer's disease biomarkers. J Alzheimers Dis 31 (2012), 659–668.
147. Liu, Z., Chen, H.H., Li, T.L., Xu, L., Du, H.Q., A cross-sectional study on cerebrospinal fluid biomarker levels in cognitively normal elderly subjects with or without a family history of Alzheimer's disease. CNS Neurosci Ther 19 (2013), 38–42.
148. Honea, R.A., Swerdlow, R.H., Vidoni, E., Burns, J.M., Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 76 (2011), 822–829.
149. Honea, R.A., Swerdlow, R.H., Vidoni, E.D., Goodwin, J., Burns, J.M., Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 74 (2010), 113–120.
150. Berti, V., Mosconi, L., Glodzik, L., et al. Structural brain changes in normal individuals with a maternal history of Alzheimer's. Neurobiol Aging, 32, 2011 2325.e17-26.
151. Andrawis, J.P., Hwang, K.S., Green, A.E., et al. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging 33 (2012), 856–866.
152. Reiter, K., Alpert, K.I., Cobia, D.J., et al. Cognitively normal individuals with AD parents may be at risk for developing aging-related cortical thinning patterns characteristic of AD. Neuroimage 61 (2012), 525–532.
153. Mosconi, L., de Leon, M., Murray, J., et al. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. J Alzheimers Dis 27 (2011), 483–490.
154. Debette, S., Wolf, P.A., Beiser, A., et al. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology 73 (2009), 2071–2078.
155. Corder, E.H., Saunders, A.M., Strittmatter, W.J., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993), 921–923.
156. Strittmatter, W.J., Saunders, A.M., Schmechel, D., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90 (1993), 1977–1981.
157. Pericak-Vance, M.A., Bebout, J.L., Gaskell, P.C. Jr., et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet 48 (1991), 1034–1050.
158. Mahley, R.W., Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240 (1988), 622–630.
159. Mahley, R.W., Rall, S.C. Jr., Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1 (2000), 507–537.
160. Mahley, R.W., Huang, Y., Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron 76 (2012), 871–885.
161. Mahley, R.W., Weisgraber, K.H., Huang, Y., Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 103 (2006), 5644–5651.
162. Chen, H.K., Ji, Z.S., Dodson, S.E., et al. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem 286 (2011), 5215–5221.
163. Valla, J., Yaari, R., Wolf, A.B., et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis 22 (2010), 307–313.
164. Carrieri, G., Bonafe, M., De Luca, M., et al. Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Hum Genet 108 (2001), 194–198.
165. Bekris, L.M., Galloway, N.M., Montine, T.J., Schellenberg, G.D., Yu, C.E., APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet 153B (2009), 409–417.
166. Cervantes, S., Samaranch, L., Vidal-Taboada, J.M., et al. Genetic variation in APOE cluster region and Alzheimer's disease risk. Neurobiol Aging, 32, 2011 2107.e7-17.
167. Hayden, K.M., McEvoy, J.M., Linnertz, C., et al. A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging. Alzheimers Dement 8 (2012), 381–388.
168. Johnson, S.C., La Rue, A., Hermann, B.P., et al. The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE epsilon3/epsilon3 genotype. Alzheimers Dement 7 (2011), 456–465.
169. Li, G., Bekris, L.M., Leong, L., et al. TOMM40 intron 6 poly-T length, age at onset, and neuropathology of AD in individuals with APOE varepsilon3/varepsilon3. Alzheimers Dement 9 (2013), 554–561.
170. Maruszak, A., Peplonska, B., Safranow, K., Chodakowska-Zebrowska, M., Barcikowska, M., Zekanowski, C., TOMM40 rs10524523 polymorphism's role in late-onset Alzheimer's disease and in longevity. J Alzheimers Dis 28 (2012), 309–322.
171. Potkin, S.G., Guffanti, G., Lakatos, A., et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One, 4, 2009, e6501.
172. Roses, A.D., An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch Neurol 67 (2010), 536–541.
173. Roses, A.D., Lutz, M.W., Amrine-Madsen, H., et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J 10 (2010), 375–384.
174. Takei, N., Miyashita, A., Tsukie, T., et al. Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese. Genomics 93 (2009), 441–448.
175. Guerreiro, R.J., Hardy, J., TOMM40 association with Alzheimer disease: tales of APOE and linkage disequilibrium. Arch Neurol 69 (2012), 1243–1244.
176. Cruchaga, C., Nowotny, P., Kauwe, J.S., et al. Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch Neurol 68 (2011), 1013–1019.
177. Cottrell, D.A., Blakely, E.L., Johnson, M.A., Ince, P.G., Turnbull, D.M., Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 57 (2001), 260–264.
178. Krishnan, K.J., Ratnaike, T.E., De Gruyter, H.L., Jaros, E., Turnbull, D.M., Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease. Neurobiol Aging 33 (2012), 2210–2214.
179. Coskun, P.E., Wyrembak, J., Derbereva, O., et al. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis 20:suppl 2 (2010), S293–S310.
180. Lin, M.T., Simon, D.K., Ahn, C.H., Kim, L.M., Beal, M.F., High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet 11 (2002), 133–145.
181. Webster, M.T., Pearce, B.R., Bowen, D.M., Francis, P.T., The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J Neural Transm 105 (1998), 839–853.
182. Gasparini, L., Racchi, M., Benussi, L., et al. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett 231 (1997), 113–117.
183. Gabuzda, D., Busciglio, J., Chen, L.B., Matsudaira, P., Yankner, B.A., Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269 (1994), 13623–13628.
184. Scheffler, K., Krohn, M., Dunkelmann, T., et al. Mitochondrial DNA polymorphisms specifically modify cerebral beta-amyloid proteostasis. Acta Neuropathol 124 (2012), 199–208.
185. Fukui, H., Diaz, F., Garcia, S., Moraes, C.T., Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 104 (2007), 14163–14168.
186. Pinto, M., Pickrell, A.M., Fukui, H., Moraes, C.T., Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formation. Neurobiol Aging 34 (2013), 2399–2407.
187. Kukreja, L., Kujoth, G.C., Prolla, T.A., Van Leuven, F., Vassar, R., Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease. Mol Neurodegener, 9, 2014, 16.
188. Dumont, M., Stack, C., Elipenahli, C., et al. PGC-1alpha overexpression exacerbates beta-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease. FASEB J 28 (2014), 1745–1755.
189. Kang, J.E., Lim, M.M., Bateman, R.J., et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326 (2009), 1005–1007.
190. Roh, J.H., Jiang, H., Finn, M.B., et al. Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. J Exp Med 211 (2014), 2487–2496.
191. Bero, A.W., Yan, P., Roh, J.H., et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 14 (2011), 750–756.
192. Yamamoto, K., Tanei, Z., Hashimoto, T., et al. Chronic optogenetic activation augments abeta pathology in a mouse model of Alzheimer disease. Cell Rep 11 (2015), 859–865.
193. Brody, D.L., Magnoni, S., Schwetye, K.E., et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 321 (2008), 1221–1224.
194. Vlassenko, A.G., Vaishnavi, S.N., Couture, L., et al. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc Natl Acad Sci USA 107 (2010), 17763–17767.
195. Escobar-Khondiker, M., Hollerhage, M., Muriel, M.P., et al. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci 27 (2007), 7827–7837.
196. Szabados, T., Dul, C., Majtenyi, K., Hargitai, J., Penzes, Z., Urbanics, R., A chronic Alzheimer's model evoked by mitochondrial poison sodium azide for pharmacological investigations. Behav Brain Res 154 (2004), 31–40.
197. Hoglinger, G.U., Lannuzel, A., Khondiker, M.E., et al. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 95 (2005), 930–939.
198. Rottscholl, R., Haegele, M., Jainsch, B., et al. Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wild-type and MAPT transgenic mice. J Neurochem 139 (2016), 624–639.
199. Yamada, E.S., Respondek, G., Mussner, S., et al. Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. Exp Neurol 253 (2014), 113–125.
200. Yanagisawa, M., Planel, E., Ishiguro, K., Fujita, S.C., Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease. FEBS Lett 461 (1999), 329–333.
201. Zhao, Y., Tseng, I.C., Heyser, C.J., et al. Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. Neuron 87 (2015), 963–975.
202. Hoglinger, G.U., Melhem, N.M., Dickson, D.W., et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43 (2011), 699–705.
203. Blass, J.P., Baker, A.C., Ko, L., Black, R.S., Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol 47 (1990), 864–869.
204. Blass, J.P., Baker, A.C., Ko, L., Sheu, R.K., Black, R.S., Expression of ‘Alzheimer antigens’ in cultured skin fibroblasts. Arch Neurol 48 (1991), 709–717.
205. Swerdlow, R.H., Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res 85 (2007), 3416–3428.
206. Poste, G., Reeve, P., Enucleation of mammalian cells by cytochalasin B. II. Formation of hybrid cells and heterokaryons by fusion of anucleate and nucleated cells. Exp Cell Res 73 (1972), 287–294.
207. King, M.P., Attardi, G., Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246 (1989), 500–503.
208. Clark, M.A., Shay, J.W., Mitochondrial transformation of mammalian cells. Nature 295 (1982), 605–607.
209. Bunn, C.L., Wallace, D.C., Eisenstadt, J.M., Cytoplasmic inheritance of chloramphenicol resistance in mouse tissue culture cells. Proc Natl Acad Sci USA 71 (1974), 1681–1685.
210. Wallace, D.C., Bunn, C.L., Eisenstadt, J.M., Cytoplasmic transfer of chloramphenicol resistance in human tissue culture cells. J Cell Biol 67 (1975), 174–188.
211. Morais, R., Desjardins, P., Turmel, C., Zinkewich-Peotti, K., Development and characterization of continuous avian cell lines depleted of mitochondrial DNA. In Vitro Cell Dev Biol 24 (1988), 649–658.
212. Desjardins, P., de Muys, J.M., Morais, R., An established avian fibroblast cell line without mitochondrial DNA. Somat Cell Mol Genet 12 (1986), 133–139.
213. Desjardins, P., Frost, E., Morais, R., Ethidium bromide-induced loss of mitochondrial DNA from primary chicken embryo fibroblasts. Mol Cell Biol 5 (1985), 1163–1169.
214. Ephrussi, B., Hottinger, H., Chimenes, A., Action de l'acriflavine sur les levures, I: la mutation “petite clonie”. Ann Inst Pasteur, 76, 1949, 531.
215. King, M.P., Koga, Y., Davidson, M., Schon, E.A., Defects in mitochondrial protein synthesis and respiratory chain activity segregate with the tRNA(Leu(UUR)) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Mol Cell Biol 12 (1992), 480–490.
216. Masucci, J.P., Davidson, M., Koga, Y., Schon, E.A., King, M.P., In vitro analysis of mutations causing myoclonus epilepsy with ragged-red fibers in the mitochondrial tRNA(Lys)gene: two genotypes produce similar phenotypes. Mol Cell Biol 15 (1995), 2872–2881.
217. Michikawa, Y., Mazzucchelli, F., Bresolin, N., Scarlato, G., Attardi, G., Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 286 (1999), 774–779.
218. Chomyn, A., Martinuzzi, A., Yoneda, M., et al. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc Natl Acad Sci USA 89 (1992), 4221–4225.
219. Chomyn, A., Lai, S.T., Shakeley, R., Bresolin, N., Scarlato, G., Attardi, G., Platelet-mediated transformation of mtDNA-less human cells: analysis of phenotypic variability among clones from normal individuals—and complementation behavior of the tRNALys mutation causing myoclonic epilepsy and ragged red fibers. Am J Hum Genet 54 (1994), 966–974.
220. Hofhaus, G., Johns, D.R., Hurko, O., Attardi, G., Chomyn, A., Respiration and growth defects in transmitochondrial cell lines carrying the 11778 mutation associated with Leber's hereditary optic neuropathy. J Biol Chem 271 (1996), 13155–13161.
221. Miller, S.W., Trimmer, P.A., Parker, W.D. Jr., Davis, R.E., Creation and characterization of mitochondrial DNA-depleted cell lines with “neuronal-like” properties. J Neurochem 67 (1996), 1897–1907.
222. Swerdlow, R.H., Parks, J.K., Miller, S.W., et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40 (1996), 663–671.
223. Parker, W.D. Jr., Boyson, S.J., Parks, J.K., Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26 (1989), 719–723.
224. Krige, D., Carroll, M.T., Cooper, J.M., Marsden, C.D., Schapira, A.H., Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32 (1992), 782–788.
225. Benecke, R., Strumper, P., Weiss, H., Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 116:pt 6 (1993), 1451–1463.
226. Parker, W.D., Sporadic neurologic disease and the electron transport chain: a hypothesis. Pascuzzi, R.M., (eds.), Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, 1990, Indiana University Printing Services, Bloomington, Indiana.
227. Davis, R.E., Miller, S., Herrnstadt, C., et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci USA 94 (1997), 4526–4531.
228. Davis, R.E., Miller, S., Herrnstadt, C., et al. Retraction. Proc Natl Acad Sci USA, 95, 1998, 12069.
229. Sheehan, J.P., Swerdlow, R.H., Miller, S.W., et al. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 17 (1997), 4612–4622.
230. Swerdlow, R.H., Parks, J.K., Cassarino, D.S., et al. Cybrids in Alzheimer's disease: a cellular model of the disease?. Neurology 49 (1997), 918–925.
231. Cardoso, S.M., Santana, I., Swerdlow, R.H., Oliveira, C.R., Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 89 (2004), 1417–1426.
232. Silva, D.F., Selfridge, J.E., Lu, J., et al. Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum Mol Genet 22 (2013), 3931–3946.
233. Ito, S., Ohta, S., Nishimaki, K., et al. Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease. Proc Natl Acad Sci USA 96 (1999), 2099–2103.
234. Bijur, G.N., Davis, R.E., Jope, R.S., Rapid activation of heat shock factor-1 DNA binding by H2O2 and modulation by glutathione in human neuroblastoma and Alzheimer's disease cybrid cells. Brain Res Mol Brain Res 71 (1999), 69–77.
235. Cassarino, D.S., Swerdlow, R.H., Parks, J.K., Parker, W.D. Jr., Bennett, J.P. Jr., Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun 248 (1998), 168–173.
236. De Sarno, P., Bijur, G.N., Lu, R., Davis, R.E., Jope, R.S., Alterations in muscarinic receptor-coupled phosphoinositide hydrolysis and AP-1 activation in Alzheimer's disease cybrid cells. Neurobiol Aging 21 (2000), 31–38.
237. Ghosh, S.S., Swerdlow, R.H., Miller, S.W., Sheeman, B., Parker, W.D. Jr., Davis, R.E., Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann N Y Acad Sci 893 (1999), 176–191.
238. Khan, S.M., Cassarino, D.S., Abramova, N.N., et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol 48 (2000), 148–155.
239. Onyango, I.G., Tuttle, J.B., Bennett, J.P. Jr., Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol Cell Neurosci 29 (2005), 333–343.
240. Onyango, I.G., Bennett, J.P. Jr., Tuttle, J.B., Endogenous oxidative stress in sporadic Alzheimer's disease neuronal cybrids reduces viability by increasing apoptosis through pro-death signaling pathways and is mimicked by oxidant exposure of control cybrids. Neurobiol Dis 19 (2005), 312–322.
241. Onyango, I.G., Ahn, J.Y., Tuttle, J.B., Bennett, J.P. Jr., Swerdlow, R.H., Nerve growth factor attenuates oxidant-induced beta-amyloid neurotoxicity in sporadic Alzheimer's disease cybrids. J Neurochem 114 (2010), 1605–1618.
242. Thiffault, C., Bennett, J.P. Jr., Cyclical mitochondrial deltapsiM fluctuations linked to electron transport, F0F1 ATP-synthase and mitochondrial Na +/Ca + 2 exchange are reduced in Alzheimer's disease cybrids. Mitochondrion 5 (2005), 109–119.
243. Trimmer, P.A., Swerdlow, R.H., Parks, J.K., et al. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol 162 (2000), 37–50.
244. Trimmer, P.A., Borland, M.K., Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement. Antioxid Redox Signal 7 (2005), 1101–1109.
245. Zhang, H., Liu, Y., Lao, M., Ma, Z., Yi, X., Puerarin protects Alzheimer's disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways. Exp Gerontol 46 (2011), 30–37.
246. Silva, D.F., Santana, I., Esteves, A.R., et al. Prodromal metabolic phenotype in MCI cybrids: implications for Alzheimer's disease. Curr Alzheimer Res 10 (2013), 180–190.
247. Gan, X., Huang, S., Wu, L., et al. Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell. Biochim Biophys Acta 1842 (2014), 220–231.
248. Gan, X., Wu, L., Huang, S., et al. Oxidative stress-mediated activation of extracellular signal-regulated kinase contributes to mild cognitive impairment-related mitochondrial dysfunction. Free Radic Biol Med 75 (2014), 230–240.
249. Yu, Q., Fang, D., Swerdlow, R.H., Yu, H., Chen, J.X., Yan, S.S., Antioxidants rescue mitochondrial transport in differentiated Alzheimer's disease trans-mitochondrial cybrid cells. J Alzheimers Dis 54 (2016), 679–690.
250. Costa, R.O., Ferreiro, E., Martins, I., et al. Amyloid beta-induced ER stress is enhanced under mitochondrial dysfunction conditions. Neurobiol Aging, 33, 2012 824.e5-16.
251. Jeong, J.H., Yum, K.S., Chang, J.Y., et al. Dose-specific effect of simvastatin on hypoxia-induced HIF-1alpha and BACE expression in Alzheimer's disease cybrid cells. BMC Neurol, 15, 2015, 127.
252. Trimmer, P.A., Keeney, P.M., Borland, M.K., et al. Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. Neurobiol Dis 15 (2004), 29–39.
253. Nunomura, A., Perry, G., Aliev, G., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60 (2001), 759–767.
254. Khan, S.M., Smigrodzki, R.M., Swerdlow, R.H., Cell and animal models of mtDNA biology: progress and prospects. Am J Physiol Cell Physiol 292 (2007), C658–C669.
255. Meissner, C., Mohamed, S.A., Klueter, H., Hamann, K., von Wurmb, N., Oehmichen, M., Quantification of mitochondrial DNA in human blood cells using an automated detection system. Forensic Sci Int 113 (2000), 109–112.
256. Lu, J., Wang, K., Rodova, M., et al. Polymorphic variation in cytochrome oxidase subunit genes. J Alzheimers Dis 21 (2010), 141–154.
257. Sims, N.R., Finegan, J.M., Blass, J.P., Altered glucose metabolism in fibroblasts from patients with Alzheimer's disease. N Engl J Med 313 (1985), 638–639.
258. Sims, N.R., Finegan, J.M., Blass, J.P., Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease. Ann Neurol 21 (1987), 451–457.
259. Sims, N.R., Finegan, J.M., Blass, J.P., Bowen, D.M., Neary, D., Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res 436 (1987), 30–38.
260. Blass, J.P., Zemcov, A., Alzheimer's disease. A metabolic systems degeneration?. Neurochem Pathol 2 (1984), 103–114.
261. Hoyer, S., Brain oxidative energy and related metabolism, neuronal stress, and Alzheimer's disease: a speculative synthesis. J Geriatr Psychiatry Neurol 6 (1993), 3–13.
262. Beal, M.F., Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38 (1995), 357–366.
263. Reddy, P.H., Beal, M.F., Are mitochondria critical in the pathogenesis of Alzheimer's disease?. Brain Res Brain Res Rev 49 (2005), 618–632.
264. Moreira, P.I., Carvalho, C., Zhu, X., Smith, M.A., Perry, G., Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 1802 (2010), 2–10.
265. Moreira, P.I., Cardoso, S.M., Santos, M.S., Oliveira, C.R., The key role of mitochondria in Alzheimer's disease. J Alzheimers Dis 9 (2006), 101–110.
266. Zhu, X., Perry, G., Moreira, P.I., et al. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis 9 (2006), 147–153.
267. Brinton, R.D., The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 31 (2008), 529–537.
268. Mancuso, M., Siciliano, G., Filosto, M., Murri, L., Mitochondrial dysfunction and Alzheimer's disease: new developments. J Alzheimers Dis 9 (2006), 111–117.
269. Swerdlow, R.H., Burns, J.M., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20:suppl 2 (2010), S265–S279.
270. Swerdlow, R.H., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol 218 (2009), 308–315.
271. Swerdlow, R.H., Khan, S.M., A “mitochondrial cascade hypothesis” for sporadic Alzheimer's disease. Med Hypotheses 63 (2004), 8–20.
272. Swerdlow, R.H., Burns, J.M., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta 1842 (2014), 1219–1231.
273. Giles, R.E., Blanc, H., Cann, H.M., Wallace, D.C., Maternal inheritance of human mitochondrial DNA. Proc Natl Acad Sci USA 77 (1980), 6715–6719.
274. Jack, C.R. Jr., Wiste, H.J., Lesnick, T.G., et al. Brain beta-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
275. Burns, J.M., Swerdlow, R.H., Backwaters and rapids on the amyloid river. Neurology 80 (2013), 878–879.
276. Swerdlow, R.H., Bioenergetic medicine. Br J Pharmacol 171 (2014), 1854–1869.
277. Swerdlow, R.H., Mitochondrial medicine and the neurodegenerative mitochondriopathies. Pharmaceuticals 2 (2009), 150–167.
278. Swerdlow, R.H., Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des 17 (2011), 3356–3373.
279. Swerdlow, R.H., Treating neurodegeneration by modifying mitochondria: potential solutions to a “complex” problem. Antioxid Redox Signal 9 (2007), 1591–1603.
280. Swerdlow, R.H., Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox Res 22 (2012), 182–194.